De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients

American Journal of Transplantation

Volumn 13, Issue 6, 2013, Pages 1541-1548

  Kaneku, H ^a   O'Leary, J G ^b   Banuelos, N ^c   Jennings, L W ^b   Susskind, B M ^b   Klintmalm, G B ^b   Terasaki, P I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Allograft rejection; de novo donor specific HLA antibodies; graft survival; liver transplantation; patient survival; risk factors

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; DONOR SPECIFIC HLA ANTIBODY; HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MELD SCORE; ORGAN DONOR; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 85027920362     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12212     Document Type: Article

References (45)

1. Terasaki PI, Cai J., Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
2. Morales-Buenrostro LE, Castro R, Terasaki PI., A single human leukocyte antigen-antibody test after heart or lung transplantation is predictive of survival. Transplantation 2008; 85: 478-481.
3. Cantarovich D, De Amicis S, Akl A, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011; 11: 2737-2746.
4. Abu-Elmagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation: Long-term outcome with special reference to the liver. Am J Transplant 2012; 12: 3047-3060.
5. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
6. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH., The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1993; 1: 60-65.
7. Farmer DG, Venick RS, Colangelo J, et al. Pretransplant predictors of survival after intestinal transplantation: Analysis of a single-center experience of more than 100 transplants. Transplantation 2010; 90: 1574-1580.
8. Terasaki PI, Ozawa M, Castro R., Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415.
9. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011; 72: 5-10.
10. Iwatsuki S, Rabin BS, Shaw BW Jr., Starzl TE., Liver transplantation against T cell-positive warm crossmatches. Transplant Proc 1984; 16: 1427-1429.
11. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715.
12. Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver transplantation: A 20-year review. Liver Transpl 2012; 18: 455-460.
13. Kamada N, Shinomiya T., Serology of liver transplantation in the rat. I. Alloantibody responses and evidence for tolerance in a nonrejector combination. Transplantation 1986; 42: 7-13.
14. Kamada N, Shinomiya T, Tamaki T, Ishiguro K., Immunosuppressive activity of serum from liver-grafted rats. Passive enhancement of fully allogeneic heart grafts and induction of systemic tolerance. Transplantation 1986; 42: 581-587.
15. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400-406.
16. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW., Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
17. Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR., Humoral rejection of rat hepatic transplants by passive transfer of serum. Transplant Proc 1987; 19: 1072-1076.
18. Lord R, Kamada N, Kobayashi E, Goto S, Sunagawa M., Immunosuppressive 40-kd protein induced by orthotopic liver transplantation in rats. Transplant Proc 1995; 27: 399-401.
19. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
20. Demetris AJ, Markus BH, Burnham J, et al. Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987; 19: 121-125.
21. Piazza A, Adorno D, Torlone N, et al. Flow cytometric analysis of antidonor-specific antibodies in liver transplant. Transplant Proc 1997; 29: 2975-2976.
22. Kasahara M, Kiuchi T, Takakura K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: Clinical significance of humoral immunity in acute rejection. Transplantation 1999; 67: 568-575.
23. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
24. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
25. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
26. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
27. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI., Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308-313.
28. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M., Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858-859.
29. Li X, Ishida H, Yamaguchi Y, Tanabe K., Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Transpl Int 2008; 21: 1145-1152.
30. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
31. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103-1109.
32. Ntokou IS, Iniotaki AG, Kontou EN, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: High immunogenicity of HLA class II graft molecules. Transpl Int 2011; 24: 1084-1093.
33. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172-177.
34. Devos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598-604.
35. Hubscher SG, Adams DH, Elias E., Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol 1990; 162: 165-171.
36. Steinhoff G, Wonigeit K, Pichlmayr R., Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394-401.
37. Gouw AS, Huitema S, Grond J, et al. Early induction of MHC antigens in human liver grafts. An immunohistologic study. Am J Pathol 1988; 133: 82-94.
38. Steinhoff G., Major histocompatibility complex antigens in human liver transplants. J Hepatol 1990; 11: 9-15.
39. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The US multicenter FK506 liver study group. N Engl J Med 1994; 331: 1110-1115.
40. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
41. Siegrist CA, Aspinall R., B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9: 185-194.
42. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB., Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
43. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
44. Bachelet T, Couzi L, Guidicelli G, et al. Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection. Am J Transplant 2011; 11: 1543-1544.
45. Singh P, Colombe BW, Francos GC, Martinez Cantarin MP, Frank AM., Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha. Transplantation 2010; 90: 220-221.